As p53 is frequently mutated and inactive in tumor cells, determining whether YAP overexpression promotes doxorubicin sensitivity in p53 mutant tumor cells will be necessary to elucidate its function in doxorubicin responsiveness. This evidence concerns the gene TP53 and neoplasm.